A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands


NCT01351103

Interventional

Phase 1

Recruiting
This primary purpose of this study is to find the recommended dose of LGK974 as a single agent and in combination with PDR001 that can be safely given to adult patients with selected solid malignancies for whom no effective standard treatment is available.
Dec 01,2011
All
18 Years
N/A
170

In order to facilitate the use of our website, we use cookies.

Please confirm if you accept our tracking cookies. When declining the cookies, you can continue visiting the website without sending data to third party services. Read our complete cookie statement here.